Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder

Launched by MACKAY MEMORIAL HOSPITAL · Jun 23, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how effective two different treatments are for women with an overactive bladder. The trial compares taking either solifenacin or mirabegron along with local estrogen to a combination treatment that includes both solifenacin and mirabegron. Researchers aim to see which option helps manage the symptoms of overactive bladder better in women who have not found relief with other treatments.

To participate in this study, women must be diagnosed with a specific type of bladder issue called detrusor overactivity, where the bladder muscles contract involuntarily. However, women who have certain health conditions or risks, such as issues with their eyes or heart, may not be eligible. Participants can expect to receive one of the treatments and will be monitored for their bladder symptoms. Importantly, this study is currently recruiting participants, so women who meet the criteria and are interested in joining can reach out for more information.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Patients with detrusor overactivity which defined as a urodynamic observation characterized by involuntary detrusor contractions during the filling phase. Those who were refractory to monotherapy with anti-muscarinics were enrolled for prospective study.
• Exclusion Criteria:
• • Postvoid urine retention before treatment
• • Women who had medical illness and contraindication for using solifenacin and mirabegron, such as narrow-angle glaucoma and hypertension
• • Concerns for using estrogen include: Women with history of cerebrovascular disease; thromboembolic disorders; gallbladder disease; known or suspected breast carcinoma; estrogen-dependent neoplasm or undiagnosed abnormal genital bleeding.